Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials

Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposu...

Descripción completa

Detalles Bibliográficos
Autores principales: REICH, Kristian, THAÇI, Diamant, STINGL, Georg, ANDERSEN, Jens Strodl, HIORT, Line Conradsen, LEXNER, Michala Oron, WINKLER, David, PAUL, Carle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574679/
https://www.ncbi.nlm.nih.gov/pubmed/35191512
http://dx.doi.org/10.2340/actadv.v102.1993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574679/
https://www.ncbi.nlm.nih.gov/pubmed/35191512
http://dx.doi.org/10.2340/actadv.v102.1993

Ejemplares similares